What is the recommended treatment for cutaneous vasculitis?

Treatment of Cutaneous Vasculitis

For isolated cutaneous small vessel vasculitis without systemic involvement, treatment should begin with identifying and eliminating triggers, followed by symptomatic management with NSAIDs, leg elevation, and avoidance of prolonged standing; if disease persists or recurs, initiate colchicine or dapsone as first-line agents.

Initial Assessment and Risk Stratification

The first critical step is determining whether you're dealing with isolated cutaneous disease versus systemic vasculitis, as this fundamentally changes management. Look specifically for:

• Constitutional symptoms (fever, weight loss, malaise)
• Hematuria or proteinuria (renal involvement)
• Gastrointestinal complaints (abdominal pain, GI bleeding)
• Ulcerative or necrotic lesions (higher risk of systemic disease)
• Pulmonary or neurologic symptoms 1, 2

Obtain a skin biopsy extending to the subcutis from the most tender, reddish or purpuric lesion. For suspected immune complex vasculitis, take a separate biopsy for direct immunofluorescence (DIF) from an early, partially blanchable macule—the type of perivascular immunoglobulin (IgA vs IgG/IgM) has prognostic significance 3, 2.

Treatment Algorithm for Cutaneous-Limited Disease

Mild, Self-Limited Disease

Most cutaneous leukocytoclastic vasculitis (LcV) with IgG- or IgM-containing immune complexes has a favorable prognosis 4:

• Eliminate triggers: Stop suspected drugs, treat infections, avoid excessive standing 5, 3
• Symptomatic management: Leg elevation, compression if edema present, NSAIDs 5, 3
• Many cases resolve with these measures alone

Persistent or Recurrent Disease

When lesions persist beyond 4-6 weeks or recur despite trigger avoidance 5, 3:

First-line agents:

• Colchicine (typical dosing 0.6 mg twice daily)
• Dapsone (50-150 mg daily after G6PD screening)

These are the consensus first-choice agents for chronic cutaneous vasculitis 3, 4.

Severe Cutaneous Disease

When hemorrhagic blisters suggest incipient skin necrosis or extensive ulceration develops 4:

• Systemic corticosteroids: Prednisone 0.5-1 mg/kg/day, taper over 4-8 weeks
• Consider adding azathioprine (up to 2 mg/kg/day) or methotrexate (up to 25 mg/week) for steroid-sparing effect in refractory cases 3

Special Considerations by Vasculitis Type

IgA Vasculitis (Henoch-Schönlein Purpura)

• In adults with severe glomerulonephritis, evidence for glucocorticoid efficacy is insufficient 4
• Focus on treating renal involvement with ACE inhibitors or ARBs based on symptoms
• Cutaneous disease often self-limited

Urticarial Vasculitis

• Start with antihistamines and dapsone or colchicine 4, 6
• For refractory cases: omalizumab, rituximab, or anti-IL-1 agents show highest success rates 6
• Systemic corticosteroids for acute flares

Cryoglobulinemic Vasculitis

• Treat underlying disease (hepatitis C, plasmacytoma) as primary intervention 4
• Plasmapheresis may be needed for severe cases

Systemic ANCA-Associated Vasculitis

If your workup reveals systemic involvement (renal, pulmonary, neurologic), this is a different disease requiring aggressive therapy:

For severe/organ-threatening disease 7, 8:

• Rituximab (preferred) or cyclophosphamide PLUS
• Glucocorticoids: Start prednisone 50-75 mg/day (or 1 mg/kg/day), taper to 5 mg/day by 4-5 months 7
• Consider avacopan to reduce glucocorticoid exposure 7

For non-organ-threatening systemic disease 7:

• Rituximab plus glucocorticoids
• Alternatives: methotrexate or mycophenolate mofetil

Critical Pitfalls to Avoid

1. Don't miss systemic involvement: Constitutional symptoms, hematuria, or necrotic lesions mandate full systemic workup including urinalysis, creatinine, chest imaging, and ANCA testing 1, 2

2. Don't confuse vasculitis with vasculopathy: Conditions like livedoid vasculopathy require antithrombotic therapy (low molecular weight heparin, warfarin), not immunosuppression 9, 4

3. Don't use cyclophosphamide for isolated cutaneous disease: Reserve this for true systemic vasculitis with organ involvement 3

4. Serial sections often needed: The main vasculitic lesion may be missed on initial histologic review 3

5. DIF timing matters: Obtain from early lesions for accurate immunoglobulin typing 2

Wound Care Considerations

For established ulcerations 9, 10:

• Pain management is critical (these wounds are typically very painful)
• Infection prophylaxis with appropriate wound care
• Compression therapy if edema present (supports healing)
• Stage-appropriate wound management alongside systemic therapy